•Johnson & Johnson's nipocalimab, branded as IMAAVY, has been granted FDA Priority Review status.
•Phase 2/3 trials showed positive results for the drug in treating warm autoimmune hemolytic anemia, a rare condition with no current FDA-approved treatments.
•Sigma Healthcare stock jumped 8% after the Australian pharmacy group walked away from a multi-billion dollar deal to acquire the UK pharmacy chain Boots.
•The US SEC published its draft Strategic Plan for FY 2026-2030, describing blockchain as having the potential to revolutionize financial infrastructure.
